Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
CompanyBankAnalystCoverageOpinionWk chg5/8 cls
CorMedix Inc. (NYSE-M:CRMD)Roth Capital PartnersScott HenryDowngradeNeutral (from buy)-6%$7.15
Henry downgraded after a significant run up in the share price to about $8 from about $1 in January. He attributes the rise to regulatory designations with the potential to speed up clinical progress and speculation surrounding the appointment of Evercore

Read the full 577 word article

How to gain access

Continue reading with a
two-week free trial.